Metformin and Rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms

Diabetes

Volumn 64, Issue 5, 2015, Pages 1632-1642

  Cifarelli, Vincenza ^a   Lashinger, Laura M ^b   Devlin, Kaylyn L ^c   Dunlap, Sarah M ^b   Huang, Jennifer ^b   Kaaks, Rudolf ^d   Pollak, Michael N ^e   Hursting, Stephen D ^b,f,g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Texas at Austin   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e MCGILL UNIVERSITY   (Canada)

^f University of North Carolina at Chapel Hill   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MICRORNA; MICRORNA 34A; NOTCH RECEPTOR; RAPAMYCIN; RESISTIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; VIMENTIN; ANTIDIABETIC AGENT; IMMUNOSUPPRESSIVE AGENT; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CANCER INHIBITION; CELL CYCLE ARREST; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OBESITY; PANCREAS CANCER; PRIORITY JOURNAL; SERUM FACTOR; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CELL CYCLE; DIABETIC DIET; DRUG EFFECTS; GENETICS; GLUCOSE INTOLERANCE; METABOLISM; MOUSE MUTANT; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PHYSIOLOGY; PREDIABETIC STATE; RANDOMIZATION;

ANIMALS; BODY WEIGHT; CELL CYCLE; DIET, DIABETIC; ENERGY INTAKE; GLUCOSE INTOLERANCE; HYPOGLYCEMIC AGENTS; IMMUNOSUPPRESSIVE AGENTS; MALE; METFORMIN; MICE; MICE, INBRED C57BL; MICE, OBESE; MICRORNAS; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PREDIABETIC STATE; RANDOM ALLOCATION; SIROLIMUS; TRANSCRIPTION FACTORS; VIMENTIN;

EID: 84964694199     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1132     Document Type: Article

References (49)

1. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care 2012;35:1835-1844.
2. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta- Analysis. JAMA 1995;273:1605-1609.
3. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta- Analysis of 36 studies. Br J Cancer 2005;92:2076-2083.
4. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer 2003;2:4.
5. Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of metformin: Therapeutic and cellular mechanisms. Drugs 1999;58(Suppl.1):31-39; discussion 75-82.
6. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777.
7. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305.
8. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18:2905-2912.
9. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Antidiabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: A systematic review and meta- Analysis. Am J Gastroenterol 2013;108: 510-519; quiz 520.
10. Suissa S, Azoulay L. Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 2012;35:2665-2673.
11. Bao B, Wang Z, Li Y, Kong D, Ali S, Banerjee S, Ahmad A, Sarkar FH. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta 2011;1815:135-146.
12. Nair V, Sreevalsan S, Basha R, et al. Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: Role of specificity protein (Sp) transcription factors. J Biol Chem 2014;289:27692-27701.
13. Hardie DG, Ross FA, Hawley SA. AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012;13:251-262.
14. Wullschleger S, Loewith R, Oppliger W, Hall MN. Molecular organization of target of rapamycin complex 2. J Biol Chem 2005;280:30697-30704.
15. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8:909- 915.
16. Bruns CJ, Koehl GE, Guba M, et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004;10:2109-2119.
17. Stephan S, Datta K, Wang E, et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 2004;10:6993-7000.
18. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
19. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008;7:3112-3118.
20. Lashinger LM, Malone LM, Brown GW, et al. Rapamycin partially mimics the anticancer effects of calorie restriction in a murine model of pancreatic cancer. Cancer Prev Res (Phila) 2011;4:1041-1051.
21. Brüning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997;88:561-572.
22. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984;44:717-726.
23. Dunlap SM, Chiao LJ, Nogueira L, et al. Dietary energy balance modulates epithelial- To-mesenchymal transition and tumor progression in murine claudinlow and basal-like mammary tumor models. Cancer Prev Res (Phila) 2012;5: 930-942.
24. Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y, Sarkar FH. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J Transl Res 2012;4:432-442.
25. Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. Asian Pac J Cancer Prev 2012;13:2485- 2489.
26. Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncol Lett 2012;3:879-884.
27. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol 2012;44:2144-2151.
28. Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 2012;5:355-364.
29. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715.
30. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 2010;17:F19-F36.
31. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-647.
32. Miska EA, Alvarez-Saavedra E, Townsend M, et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol 2004;5: R68.
33. Decker T, Hipp S, Ringshausen I, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003;101:278-285.
34. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004;10:1013-1023.
35. Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012;335: 1638-1643.
36. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001;120:1263-1270.
37. Nunez NP, Perkins SN, Smith NC, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 2008;60: 534-541.
38. Lashinger LM, Harrison LM, Rasmussen AJ, et al. Dietary energy balance modulation of Kras- And Ink4a/Arf+/-driven pancreatic cancer: The role of insulin-like growth factor-I. Cancer Prev Res (Phila) 2013;6:1046- 1055.
39. Do MT, Kim HG, Choi JH, Jeong HG. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1a/Nrf2 pathway, leading to increased susceptibility of wild- Type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic Biol Med 2014;74:21-34.
40. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009;4:e6816.
41. Jamieson NB, Morran DC, Morton JP, et al. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 2012; 18:534-545.
42. Zhang J, Tian XJ, Zhang H, et al. TGF-b-induced epithelial- To-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci Signal 2014;7:ra91.
43. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA. Metformin against TGFb-induced epithelial- To-mesenchymal transition (EMT): from cancer stem cells to aging- Associated fibrosis. Cell Cycle 2010;9:4461-4468.
44. Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol 2008;182:315-325.
45. Wang Z, Li Y, Banerjee S, Sarkar FH. Emerging role of Notch in stem cells and cancer. Cancer Lett 2009;279:8-12.
46. Leong KG, Niessen K, Kulic I, et al. Jagged1-mediated Notch activation induces epithelial- To-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007;204:2935-2948.
47. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A 2008;105:6392-6397.
48. Wang Y, Zhang Y, Yang J, et al. Genomic sequencing of key genes in mouse pancreatic cancer cells. Curr Mol Med 2012;12:331-341.
49. Li L, Li Z, Kong X, et al. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and beta-catenin signaling in pancreatic ductal adenocarcinoma cells. Gastroenterology 2014;147:485-497.e18.